Orexigen raises $90 million as it continues to ressurect Contrave
This article was originally published in Scrip
Executive Summary
Orexigen Therapeutics raised about $90 million through the sale of 5.6 million units at $15.94, consisting of a share of stock and warrant to purchase 10 shares, in an offering underwritten by Leerink Swann.